Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2020
Event: Initiation of patent infringement litigation regarding the product VIVITROL (naltrexone for extended-release injectable suspension).
Key Financial Metrics
This filing is a current report regarding a legal event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the commencement of legal proceedings. On September 9, 2020, Alkermes, Inc. and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the United States District Court, District of New Jersey, against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.
- Trigger: Teva USA submitted an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification notice alleging invalidity or non-infringement of Alkermes' U.S. Patent No. 7,919,499 (the "'499 patent").
- Patent Status: The '499 patent is listed in the FDA Orange Book and expires in October 2029.
- Legal Consequence: The lawsuit was filed within 45 days of the Notice Letter, triggering an automatic stay of FDA approval for Teva's generic ANDA for up to 30 months under the Hatch-Waxman Act.
Outlook, Risks, and Management Commentary
Management Stance: Alkermes intends to vigorously defend its intellectual property rights.
Risks and Contingencies: The outcome of the litigation is uncertain. If the court rules against Alkermes, the '499 patent could be declared invalid or unenforceable, potentially allowing Teva to launch a generic version of VIVITROL prior to the patent's 2029 expiration, which could materially impact future revenue from the product.
Investor Verification Checklist
- Verify the current status of the lawsuit filed in the District of New Jersey against Teva.
- Confirm the expiration date of U.S. Patent No. 7,919,499 (stated as October 2029) and its coverage scope.
- Monitor FDA communications regarding the stay on Teva's ANDA approval for VIVITROL.
- Assess the revenue contribution of VIVITROL to Alkermes' total portfolio to gauge potential financial impact.